Metabolic syndrome and liver transplantation: A review and guide to management

Journal of Hepatology

Volumn 53, Issue 1, 2010, Pages 199-206

  Watt, Kymberly D S ^a   Charlton, Michael R ^a  

^a MAYO CLINIC   (United States)

Author keywords

BMI; Liver disease; Metabolic syndrome; Obesity; Post liver transplant

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CERIVASTATIN; CLOFIBRATE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FELODIPINE; FENOFIBRATE; FISH OIL; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ISRADIPINE; LOOP DIURETIC AGENT; METFORMIN; MEVINOLIN; NIFEDIPINE; ORAL ANTIDIABETIC AGENT; PRAVASTATIN; RAPAMYCIN; SIMVASTATIN; SULFONYLUREA DERIVATIVE; TACROLIMUS;

CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG DOSE INCREASE; DYSLIPIDEMIA; FATTY LIVER; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS C; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LEG EDEMA; LIVER GRAFT REJECTION; LIVER TOXICITY; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; MUSCLE INJURY; OBESITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; UNSPECIFIED SIDE EFFECT; CARDIOVASCULAR DISEASES; COMPLICATION; POSTOPERATIVE COMPLICATIONS; RECURRENT DISEASE; RENAL INSUFFICIENCY;

CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DYSLIPIDEMIAS; FATTY LIVER; HEPATITIS C; HUMANS; HYPERTENSION; IMMUNOSUPPRESSION; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; OBESITY; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RENAL INSUFFICIENCY;

EID: 77953121975     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.01.040     Document Type: Review

References (104)

1. Angulo P. Nonalcoholic fatty liver disease and liver transplantation. Liver Transpl 12 (2006) 523-534
2. Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol 2 (2004) 1048-1058
3. Adam R., McMaster O., O'Grady J.G., Castaing D., Klempnauer J.L., Jamieson N., et al. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl 9 (2003) 1231-1243
4. Grundy S., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
5. Grundy S.M., Becker D., Clark L.T., Cooper R.S., Denke M.A., Howard W.J., et al. NIH, third report of the National Cholesterol Education Program expert panel on detection, evaluation, and treatment of high blood pressure in adults (Adult Treatment Panel III) (2001), National Institutes of Health, Bethesda, MD
6. Ford E., Giles W., and Dietz W. Prevalence of the metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Examination Survey. JAMA 287 (2002) 356-359
7. Ford E.S., Giles W.H., and Ah M. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 27 (2004) 2444-2449
8. Gami A., Witt B.J., Howard D.E., Erwin P.J., Gami L.A., Somers V.H., et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 49 (2007) 403-414
9. Girman C., Rhodes T., Mercuri M., Pyorala K., Kjekshus J., Pedersen T.R., et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/Tex-CAPS). Am J Cardiol 93 (2004) 136-141
10. Lakka H., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716
11. Tellez-Avila F., Sanchez-Avila F., Garcia-Saenz-de-Socolia M., Chavez-Tapia N.C., Granco-Gusman A.M., Lopez-Arce G., et al. Prevalence of metabolic syndrome, obesity and diabetes type 2 in cryptogenic cirrhosis. World J Gastroenterol 14 (2008) 4771-4775
12. Poonawala A., Nair S., and Thuluvath P. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 32 (2000) 689-692
13. Watt K., et al. Risk factors associated with long-term mortality after liver transplantation: an analysis of the multi-center, prospective Niddk database. Hepatology 48 (2008) 66
14. Pfitzmann R., Nussler N.C., Hippler-Benscheidt M., Neuhaus R., and Neuhaus P. Long-term results after liver transplantation. Transpl Int 21 (2008) 234-246
15. Laryea M., Watt K.D., Molinari M., Walsh M.J., McAlister V.C., Marotta P.J., et al. Metabolic syndrome in liver transplant recipients: prevalence and association with cardiovascular events. Liver Transpl 13 (2007) 1109-1114
16. Bianchi G., Marchesini G., Marzocchi R., Pinna A.D., and Zoli M. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transpl 4 (2008) 1648-1654
17. Johnston S., Morris J.K., Cramb R., Gunson B.K., and Neuberger J. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 73 (2002) 901-906
18. Vogt D., Henderson J.M., Carey W.D., and Barnes D. The long-term survival and causes of death in patients who survive at least 1 year after liver transplantation. Surgery 132 (2002) 775-780
19. Sturm R. Increases in clinically severe obesity in the United States, 1986-2000. Arch Intern Med 163 (2003) 2146-2148
20. Palaniappan L., Carnethon M.R., Wang Y., Hanley A.J., Fortmann S.P., Haffner S.M., et al. Predictors of the incident metabolic syndrome in adults: the Insulin Resistance Atherosclerosis Study. Diabetes Care 27 (2004) 788-793
21. Alberti K., Zimmet P., and Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 366 (2005) 1059-1062
22. Adams R., Appleton S., Wilson D.H., Taylor A.W., Dal Grande E., Chittleborough C., et al. Population comparison of two clinical approaches to the metabolic syndrome: implications of the new International Diabetes Federation consensus definition. Diabetes Care 8 (2005) 2777-2779
23. Bays H., Gonzales-Campoy J.M., Bray G.A., Kitabchi A.E., Bergman D.A., Schorr A.B., et al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther 6 (2008) 343-368
24. Fox C., Massaro J.M., Hoffmann U., Pou K.M., Maurovish-Horvat P., Liu C.Y., et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham heart study. Circulation 116 (2007) 39-48
25. Smith S., Lovejoy J.C., Greenway F., Ryan D., de Jonge L., De la Bretonne J., et al. Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity. Metabolism 50 (2001) 425-435
26. Everhart J.E., Lombardero M., Lake J.R., Wiesner R.H., Zetterman R.K., and Hoofnagle J.H. Weight change and obesity after liver transplantation: incidence and risk factors. Liver Transpl Surg 4 (1998) 285-296
27. Richards J., Gunson B., Johnson J., and Neuberger J. Weight gain and obesity after liver transplantation. Transpl Int 18 (2005) 461-466
28. Wawrzynowicz-Syczewska M., Karpinska E., Jurczyk K., Laurans L., and Boron-Kaczmarska A. Risk factors and dynamics of weight gain in patients after liver transplantation. Ann Transplant 14 (2009) 45-50
29. Choban P., and Flancbaum L. The impact of obesity on surgical outcomes: a review. J Am Coll Surg 185 (1997) 593-603
30. Hillingso J.G., Wettergren A., Hyoudo M., and Kirkegaard P. Obesity increases mortality in liver transplantation - the Danish experience. Transpl Int 18 (2005) 1231-1235
31. Nair S., Verma S., and Thuluvath P.J. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 35 (2002) 105-109
32. Braunfeld M.Y., Chan S., Pregler J., Neelakanta G., Sopher M.J., Busuttil R.W., et al. Liver transplantation in the morbidly obese. J Clin Anesth 8 (1996) 585-590
33. Sawyer R., Pelletier S., and Pruett T. Increased early morbidity and mortality with acceptable long-term function in severely obese patients undergoing liver transplantation. Clin Transpl 13 (1999) 126-130
34. Keeffe E.B., Gettys C., and Esquivel C.O. Liver transplantation in patients with severe obesity. Transplantation 57 (1994) 309-311
35. Fujikawa T., Fujita S., Mizuno S., Shenkman E., Vogel B., Lipori P., et al. Clinical and financial impact of obesity on the outcome of liver transplantation. Transplant Proc 38 (2006) 3612-3614
36. Nair S., Cohen D.B., Cohen M.P., Tan H., Maley W., and Thuluvath P.J. Postoperative morbidity, mortality, costs, and long-term survival in severely obese patients undergoing orthotopic liver transplantation. Am J Gastroenterol 96 (2001) 842-845
37. Leonard J., Heimbach J.K., Malinchoc M., Watt K., and Charlton M. The impact of obesity on longterm outcomes in liver transplant recipients - results of the NIDDK liver transplant database. Am J Transplant 8 (2008) 667-672
38. Dick A.A., Spitzer A.L., Seifert C.F., Deckert A., Carithers Jr. R.L., Reyes J.D., et al. Liver transplantation at the extremes of the body mass index. Liver Transpl 15 (2009) 968-977
39. Jensen M., Kanaley J.A., Reed J.E., and Sheedy P.F. Measurement of abdominal and visceral fat with computed tomography and dual-energy X-ray absorptiometry. Am J Clin Nutr 61 (1995) 274-278
40. Fishbein T.M., Fiel M.I., Emre S., Cubukcu O., Guy S.R., Schwartz M.E., et al. Use of livers with microvesicular fat safely expands the donor pool. Transplantation 64 (1997) 248-251
41. Christakis N.A., and Fowler J.H. The spread of obesity in a large social network over 32 years. N Engl J Med 357 (2007) 370-379
42. Stegall M.D., Everson G., Schroter G., Bilir B.M., Karrer F., and Kam I. Metabolic complications after liver transplantation. Diabetes, hypercholesterolemia, hypertension, and obesity. Transplantation 60 (1995) 1057-1060
43. Kotlyar M., and Carson S. Effects of obesity on the cytochrome P450 enzyme system. Int J Clin Pharmacol Ther 37 (1999) 8-19
44. Cassiman D., Roelants M., Vandenplas G., Van der Merwe S.W., Mertens A., Libbrecht L., et al. Orlistat treatment is safe in overweight and obese liver transplant recipients: a prospective, open label trial. Transpl Int 19 (2006) 1000-1005
45. Takata M., Campos G.M., Ciovica R., Rabi C., Rogers S.J., Cello J.P., et al. Laparoscopic bariatric surgery improves candidacy in morbidly obese patients awaiting transplantation. Surg Obes Relat Dis 4 (2008) 159-164
46. Butte J., Devaud N., Jarufe N.P., Boza C., Perez G., Torres J., et al. Sleeve gastrectomy as treatment for severe obesity after orthotopic liver transplantation. Obes Surg 17 (2007) 1517-1519
47. Campsen J., Zimmerman M., Shoen J., Wachs M., Bak T., Mandell M.S., et al. Adjustable gastric banding in a morbidly obese patient during liver transplantation. Obes Surg 18 (2008) 1625-1627
48. Megyesi C., Samols E., and Marks V. Glucose tolerance and diabetes in chronic liver disease. Lancet 2 (1967) 1051-1056
49. Perseghin G., Mazzaferro V., Sereni L.P., Regalia E., Benedini S., Bazzigaluppi E., et al. Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: effect of liver transplantation. Hepatology 31 (2000) 694-703
50. Reuben A. Long-term management of the liver transplant patient: diabetes, hyperlipidemia, and obesity. Liver Transpl 7 (2001) S13-S21
51. Moon J., Barbeito R., Faradji R.N., Ganynor J.J., and Tzakis A.G. Negative impact of new-onset diabetes mellitus on patient and graft survival after liver transplantation: long-term follow up. Transplantation 82 (2006) 1625-1628
52. Baid S., Cosimi A.B., Farrell M.L., Schoenfeld D.A., Feng S., Chung R.T., et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 72 (2001) 1066-1072
53. Colle I., Van Vlierberghe H., Troisi R., and Hemptinne B. Transplanted liver: consequences of denervation for liver functions. Anat Rec A Discov Mol Cell Evol Biol 280 (2004) 924-931
54. Schacke H., Döcke W., and Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 96 (2002) 23-43
55. Haddad E., McAlister V.C., Renoug E., Malthaner R., Kjaer M.S., and Gluud L.L. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev 18 (2006) CD005161
56. Vodenik B., Rovira J., and Campistol J.M. Mammalian target of rapamycin and diabetes: what does the current evidence tell us?. Transplant Proc 41 (2009) S31-S38
57. Veldt B., Poterucha J.J., Watt K.D., Wiesner R.H., Hay J.E., Rosen C.B., et al. Insulin resistance, serum adipokines and the risk of fibrosis progression in patients transplanted for hepatitis C: a prospective cohort study. Am J Transplant 9 (2009) 1406-1413
58. John P., and Thuluvath P. Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus. Liver Transpl 8 (2002) 708-713
59. John P., and Thuluvath P. Outcome of liver transplantation in patients with diabetes mellitus: a case-control study. Hepatology 34 (2001) 889-895
60. Yoo H., and Thuluvath P. The effect of insulin-dependent diabetes mellitus on outcome of liver transplantation. Transplantation 74 (2002) 1007-1012
61. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 32 (2009) S13-S61
62. Belfort R., Harrison S.A., Brown K., Darland C., Finch J., Hardies H., et al. A placebo-controlled trial pioglitazone in subjects with non-alcoholic steatohepatitis. N Engl J Med 355 (2006) 2297-2307
63. Lutchman G., Modi A., Kleiner D.E., Promrat K., Heller T., Ghany M., et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 46 (2007) 424-429
64. Bonkovsky H.L., Azar R., Bird S., Szabo G., and Banner B. Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone. Dig Dis Sci 47 (2002) 1632-1637
65. Nathan D.M. Rosiglitazone and cardiotoxicity - weighing the evidence. N Engl J Med 357 (2007) 64-66
66. Gisbert C., Prieto M., Berenguer M., Breto M., Carrasco D., de Juan M., et al. Hyperlipidemia in liver transplant recipients: prevalence and risk factors. Liver Transpl Surg 3 (1997) 416-422
67. Neal D., Tom B.D., Luan J., Wareham N.J., Gimson A.E., Delriviere L.D., et al. Is there disparity between risk and incidence of cardiovascular disease after liver transplant?. Transplantation 77 (2004) 93-99
68. Roy A., Kneteman N., Lilly L., Marotta P., Peltekian K., Scudamore C., et al. Tacrolimus as intervention in the treatment of hyperlipidemia after liver transplant. Transplantation 82 (2006) 494-500
69. Canzanello V.J., Schwartz L., Taler S.J., Textor S.C., Wiesner R.H., Porayko M.K., et al. Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus (FK 506). Liver Transpl Surg 3 (1997) 1-9
70. Sanchez E.Q., Martin A.P., Ikegami T., Uemura T., Narasimhan G., Goldstein R.M., et al. Sirolimus conversion after liver transplantation: improvement in measured glomerular filtration rate after 2 years. Transplant Proc 37 (2005) 4416-4423
71. Trotter J., Wachs M.E., Trouillot T.E., Bak T., Kugelmas M., Kam I., et al. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus. Liver Transpl 7 (2001) 401-408
72. Morrisett J.D., Abdel-Fattah G., and Kahan B.D. Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplant Proc 35 (2003) 143S-150S
73. Deters M., Klabunde T., Meyer H., Resch K., and Kaever V. Effects of curcumin on cyclosporine-induced cholestasis and hypercholesterolemia and on cyclosporine metabolism in the rat. Planta Med 69 (2003) 337-343
74. Chan F.K., Zhang Y., Lee S.S., and Shaffer E.A. The effects of liver transplantation and cyclosporine on bile formation and lipid composition: an experimental study in the rat. J Hepatol 28 (1998) 329-336
75. Muñoz S. Hyperlipidemia and other coronary risk factors after orthotopic liver transplantation: pathogenesis, diagnosis, and management. Liver Transpl Surg 1 (1995) 29-38
76. Klintmalm G.B., Washburn W.K., Rudich S.M., Heffron R.G., Teperman L.W., Fasola C., et al. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl 13 (2007) 1521-1531
77. Martin J., Cavanaugh T.M., Trumbull L., Bass M., Weber Jr. F., Aranda-Michel J., et al. Incidence of adverse events with HMG-CoA reductase inhibitors in liver transplant patients. Clin Transplant 22 (2008) 113-119
78. Asberg A. Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients. Drugs 63 (2003) 367-378
79. Mück W., Neal D.A., Bois O., Voith Bm Hasan R., and Alexander G.J. Tacrolimus/cerivastatin interaction study in liver transplant recipients. Br J Clin Pharmacol 52 (2001) 213-215
80. McKenney J., and Sica D. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. Pharmacotherapy 27 (2007) 715-728
81. Lee S., Gura K., and Puder M. Omega-3 fatty acids and liver disease. Hepatology 45 (2007) 841-845
82. Watson P.D., Joy P.S., Nkonde C., Hessen S.E., and Karalis D.G. Comparison of bleeding complications with omega-3 fatty acids + aspirin + clopidogrel versus aspirin + clopidogrel in patients with cardiovascular disease. Am J Cardiol 104 (2009) 1052-1054
83. Almutairi F., Peterson T.C., Molinari M., Walsh M.J., Alwayn I., and Peltekian K.M. Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia. Liver Transpl 15 (2009) 504-508
84. Canzanello V., Textor S.C., Taler S.J., Schwartz L.L., Porayko M.K., Wiesner R.H., et al. Late hypertension after liver transplantation: a comparison of cyclosporine and tacrolimus (FK 506). Liver Transpl Surg 4 (1998) 328-334
85. Gonwa T., Mendez R., Yang H.C., Weinstein S., Jensik S., Steinberg S., et al. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. Transplantation 75 (2003) 1213-1220
86. Textor S. De novo hypertension after liver transplantation. Hypertension 22 (1993) 257-267
87. Neal D., Brown M.J., Wilkinson I.B., Byrbe C.D., and Aklexander G.J. Hemodynamic effects of amlodipine, bisoprolol, and lisinopril in hypertensive patients after liver transplantation. Transplantation 77 (2004) 748-750
88. Lubel J., Herath C.B., Burrell L.M., and Angus P.W. Liver disease and the renin-angiotensin system: recent discoveries and clinical implications. J Gastroenterol Hepatol 23 (2008) 1327-1338
89. Chobanian A., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289 (2003) 2560-2572
90. Carey W.D., Dumot J.A., Pimentel R.R., Barnes D.S., Hobbs R.E., Henderson J.M., et al. The prevalence of coronary artery disease in liver transplant candidates over age 50. Transplantation 59 (1995) 859-864
91. Tiukinhoy-Laing S.D., Rossi J.S., Bayram M., De Luca L., Gafoor S., Blei A., et al. Cardiac hemodynamic and coronary angiographic characteristics of patients being evaluated for liver transplantation. Am J Cardiol 98 (2006) 178-181
92. Diedrich D.A., Findlay J.Y., Harrison B.A., and Rosen C.B. Influence of coronary artery disease on outcomes after liver transplantation. Transplant Proc 40 (2008) 3554-3557
93. Gastaldelli A., Kozakova M., Hojlund K., Flyvbjerg A., Favuzzi A., Mitrakou A., et al. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 49 (2009) 1537-1544
94. Wilson P.W., and Grundy S.M. The metabolic syndrome: practical guide to origins and treatment: Part I. Circulation 108 (2003) 1422-1424
95. Pawarode A., Fine D.M., and Thuluvath P.J. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 9 (2003) 741-747
96. Charlton M., Kasparova P., Weston S., Lindor K., Maor-kendler Y., Wiesner R.H., et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 7 (2001) 608-614
97. Contos M.J., Cales W., Sterling R.K., Luketic V.A., Schiffman M.L., Mills A.S., et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 7 (2001) 363-373
98. Malik S.M., deVera M.E., Fontes P., Shaikh O., and Ahmad J. Outcome after liver transplantation for NASH cirrhosis. Am J Transplant 9 (2009) 782-793
99. Seo S., Maganti K., Khehra M., Ramsamooj R., Tsodikov A., Bowlus C., et al. De novo nonalcoholic fatty liver disease after liver transplantation. Liver Transpl 13 (2007) 844-847
100. Hanouneh I.A., Feldstein A.E., McCullough A.J., Miller C., Aucejo F., Yerian L., et al. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl 14 (2008) 1287-1293
101. Romero-Gomez M., Del Mar Viloria M., Andrada R.J., Salmeron J., Diago M., et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128 (2005) 636-641
102. Chen T., Jia H., Li J., Chen X., Zhou H., and Tian H. New onset diabetes mellitus after liver transplantation and hepatitis C virus infection: meta-analysis of clinical studies. Transpl Int 22 (2009) 408-415
103. Syed G.H., Amako Y., and Siddiqui A. Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab 21 (2010) 33-40
104. Corey K.E., Kane E., Munroe C., Barlow L.L., Zheng H., and Chung R.T. Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology 50 (2009) 1030-1037